FibroGen (NASDAQ:FGEN) Announces Earnings Results, Hits Estimates

FibroGen (NASDAQ:FGEN) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08), Zacks reports. The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million.

FibroGen Trading Down 21.8 %

NASDAQ FGEN opened at $0.35 on Wednesday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.80. The company has a 50 day moving average of $0.50 and a 200-day moving average of $0.43. The company has a market cap of $35.07 million, a price-to-earnings ratio of -0.28 and a beta of 0.82.

Wall Street Analyst Weigh In

FGEN has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Tuesday. StockNews.com initiated coverage on FibroGen in a report on Friday, March 14th. They set a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.